N-acetylcysteine in non-acetaminophen-induced acute liver failure: a systematic review and meta-analysis of prospective studies.
Date
2021-07-14Journal
Przeglad GastroenterologicznyPublisher
TermediaType
Article
Metadata
Show full item recordSee at
https://doi.org/10.5114/pg.2021.107797https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35371352/
Abstract
A total of 672 patients were included in this meta-analysis from 5 prospective studies (NAC group: n = 334; control group: n = 338). Viral hepatitis (45.8% vs. 32.8%) followed by drug-induced liver injury (24.6% vs. 27.5%), indeterminate cause (13.2% vs. 21.6%) and autoimmune hepatitis (6.6% vs. 8.9%) were the most common etiologies of ALF in the treatment group and control group respectively. Treatment with N-acetylcysteine improved the transplant-free survival significantly (55.1% vs. 28.1%; RR = 0.56; 95% CI: 0.33-0.94) whereas the overall survival was not improved with NAC (71% vs. 59.8%; RR = 0.73; 95% CI: 0.48-1.09). The NAC treatment was associated with shorter hospital stay (standard difference in means (SMD) = -1.62; 95% CI: -1.84 to -1.40, p < 0.001).Rights/Terms
Copyright © 2022 Termedia.Identifier to cite or link to this item
http://hdl.handle.net/10713/18487ae974a485f413a2113503eed53cd6c53
10.5114/pg.2021.107797